322 related articles for article (PubMed ID: 20818871)
21. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
22. [Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].
Pozdzik AA; Debiec H; I Brochériou ; Husson C; Rorive S; Broeders N; Le Moine A; Ronco P; Nortier J
Rev Med Brux; 2015; 36(3):166-71. PubMed ID: 26372979
[TBL] [Abstract][Full Text] [Related]
23. Anti-PLA2R antibody in a secondary cause of membranous nephropathy.
Hari Krishna Reddy M; Kumar AC; Sangeetha B; Ram R; Siva Kumar V
Nephrology (Carlton); 2018 Jan; 23(1):94-95. PubMed ID: 29250915
[No Abstract] [Full Text] [Related]
24. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
Anjum N; Nabi Z
J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554
[TBL] [Abstract][Full Text] [Related]
25. A case report of breast cancer and membranous nephropathy with positive anti phospholipase A2 receptor antibodies.
Mathew D; Gupta S; Ashman N
BMC Nephrol; 2021 Sep; 22(1):324. PubMed ID: 34592934
[TBL] [Abstract][Full Text] [Related]
26. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
27. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Netti GS; Ranieri E
G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
[TBL] [Abstract][Full Text] [Related]
28. Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Huang B; Zhang Y; Wang L; Wu Q; Li T; Zhang J; Zhang Q; Sheng H; Bao J; Hu Z
Front Immunol; 2020; 11():837. PubMed ID: 32425952
[No Abstract] [Full Text] [Related]
29. PLA2R related primary membranous nephropathy in a hepatitis C positive patient.
Ramachandran R; Yadav AK; Kumar V; Varma A; Taneja S; Nada R; Gupta KL; Jha V
Nephrology (Carlton); 2018 Mar; 23(3):288. PubMed ID: 29460999
[No Abstract] [Full Text] [Related]
30. PLA2R and membranous nephropathy: A 3 year prospective Australian study.
Hill PA; McRae JL; Dwyer KM
Nephrology (Carlton); 2016 May; 21(5):397-403. PubMed ID: 26369693
[TBL] [Abstract][Full Text] [Related]
31. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
Seitz-Polski B; Payré C; Ambrosetti D; Albano L; Cassuto-Viguier E; Berguignat M; Jeribi A; Thouret MC; Bernard G; Benzaken S; Lambeau G; Esnault VL
Nephrol Dial Transplant; 2014 Dec; 29(12):2334-42. PubMed ID: 25063424
[TBL] [Abstract][Full Text] [Related]
32. [Membranous glomerulonephritis: better therapy with autoantibody monitoring?].
Stahl RA; Hoxha E; Helmchen U
Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1733-7. PubMed ID: 21877306
[TBL] [Abstract][Full Text] [Related]
33. Ischemic stroke in anti-phospholipase A2 receptor antibody-positive primary membranous nephropathy: clinical and neuroimaging characteristics.
Zhang J; Shu JL; You Q; Zhang W; Huang YN
Chin Med J (Engl); 2020 Feb; 133(3):361-363. PubMed ID: 31929373
[TBL] [Abstract][Full Text] [Related]
34. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
Gödel M; Grahammer F; Huber TB
N Engl J Med; 2015 Mar; 372(11):1073. PubMed ID: 25760365
[No Abstract] [Full Text] [Related]
35. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
Meyer-Schwesinger C; Lambeau G; Stahl RA
N Engl J Med; 2015 Mar; 372(11):1074-5. PubMed ID: 25760364
[No Abstract] [Full Text] [Related]
36. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Kanigicherla D; Gummadova J; McKenzie EA; Roberts SA; Harris S; Nikam M; Poulton K; McWilliam L; Short CD; Venning M; Brenchley PE
Kidney Int; 2013 May; 83(5):940-8. PubMed ID: 23364522
[TBL] [Abstract][Full Text] [Related]
37. Membranous nephropathy and malignancy.
Beck LH
Semin Nephrol; 2010 Nov; 30(6):635-44. PubMed ID: 21146128
[TBL] [Abstract][Full Text] [Related]
38. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.
Obrisca B; Ismail G; Jurubita R; Baston C; Andronesi A; Mircescu G
Biomed Res Int; 2015; 2015():249740. PubMed ID: 26576418
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
[TBL] [Abstract][Full Text] [Related]
40. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
